Related Experiment Video
Updated: Mar 17, 2026
Closure of a Patent Foramen Ovale PFO: An Intervention Sequence
Published on: December 23, 2022
Whether heart blocks post perimembranous ventricular septal defect device closure remain threatening: how could
Yifei Li1,2, Kaiyu Zhou1,2,3, Yimin Hua1,2,3
1Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Insights
Transcatheter closure using the Modified Amplatzer-type Occluder is safe for perimembranous ventricular septal defects (pmVSD). This method shows effective outcomes with manageable complications, though wider adoption is needed.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pediatric Cardiology
Background:
- Transcatheter closure offers an alternative to surgery for ventricular septal defects (VSD).
- The Amplatzer VSD Occluder faced FDA non-approval due to a high incidence of complete atrioventricular block (cAVB) at 6.8% compared to surgical closure (1-2%).
- Device closure for pmVSD is a routine procedure in China.
Purpose of the Study:
- To review publications on cAVB following device closure for VSD.
- To summarize long-term follow-up data for the Modified Amplatzer-type Occluder.
- To analyze the contribution and limitations of research from China in this field.
Main Methods:
- Literature review of cAVB after device closure.
- Summarization of long-term follow-up data for the Modified Amplatzer-type Occluder.
- Visualized analysis using CiteSpace for knowledge burst mapping.
Main Results:
- The Modified Amplatzer-type Occluder demonstrates safety and efficiency for pmVSD transcatheter closure.
- Complications, including cAVB, are well-controlled with a low incidence.
- China's research has contributed to the field, but its impact is limited by dissemination methods.
Conclusions:
- Transcatheter closure of pmVSD with the Modified Amplatzer-type Occluder is a safe and effective treatment.
- Further scientific dissemination of experiences from China is needed for wider global acceptance.
- Increased evidence from China may lead to broader acceptance of this therapy worldwide.
Abstract:
Transcatheter closure has become one of the alternations of surgical treatment since 1988. However, cAVB occurred as a threatening incidence of 6.8% after Amplatzer VSD Occluder closure, which was quite higher than the incidence of 1% to 2% post-surgical closure, which leaded this kind of technique, was not approved by FDA. In this commentary, we reviewed the publications of cAVB following the device closure, and summarized current data of Modified Amplatzer-type Occluder during long-term follow-up, especially introduced the experiences from China, where this kind of treatment became a routine procedure for VSD children. Moreover, we carried our visualized analysis based on scientific literatures using CiteSpace to draw knowledge burst mapping, which revealed the development procedure on this interested topics, and demonstrated the role of China's works to make contributions in the field, and figured out the limitation of our researches, which supplied a basic understanding on why we could not impact the world. Finally, it concluded that transcatheter closure of pmVSD with Modified Amplatzer-type Occluder would be safe and efficient with low incidence of well controlled complications, but it failed to spread our experiences in a more scientific way. And, we hope this kind of therapy could be accepted in a wider region of the world with the increasing evidence from China.
More Related Videos
Related Concept Videos
01:26Mitral Stenosis III: Medical Management
01:18Dysrhythmias IV: Characteristics of Bradyarrhythmias
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:25Mitral Regurgitation III: Medical Management
01:22Mitral Stenosis I: Introduction
01:27Mitral Stenosis IV: Nursing Management